ArticleScientific reports2026
Association between circadian rhythm sleep disorders and dry eye disease: a retrospective cohort study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the association between Circadian Rhythm Sleep Disorders (CRSD) and the risk of developing dry eye disease (DED). Retrospective cohort study using real-world clinical data. A total of 48,356 patients aged ≥ 18 years with a diagnosis of CRSD and 24,185 controls who underwent polysomnography and were not diagnosed with CRSD were identified. Electronic health records from the TriNetX U.S. Collaborative Network were accessed in March 2025. CRSD was identified using International Classification of Diseases-10 codes (G47.2), and patients with prior DED diagnoses were excluded. Propensity score matching (PSM) was conducted to control demographic, clinical, and pharmacologic confounders. The primary outcome was the risk of DED at 1-, 3-, and 5-year post-index date. Adjusted hazard ratios (aHR) and Kaplan-Meier survival analyses were used to evaluate the associations. Following 1:1 PSM, 19,877 patients were included in each cohort. Dry eye disease alone was significantly more frequent in the CRSD group at 1 year (0.58% vs. 0.22%; adjusted hazard ratio [aHR], 2.31; 95% CI, 1.85-2.87; p < 0.001), 3 years (1.25% vs. 0.61%; aHR, 2.12; 95% CI, 1.82-2.47; p < 0.001), and 5 years (1.58% vs. 0.89%; aHR, 2.04; 95% CI, 1.78-2.33; p < 0.001). The cumulative incidence of DED or initiation of DED medication was also elevated at 1 year (1.61% vs. 1.15%; aHR, 1.36; 95% CI, 1.22-1.53, p < 0.001), 3 years (3.15% vs. 2.65%; aHR 1.19; 95% CI, 1.1-1.29; p = 0.004), and 5 years (4.11% vs. 3.43%; aHR, 1.16; 95% CI, 1.08-1.25, p < 0.001). CRSD was associated with an increased risk of DED across all time points. These findings suggest a potential link between circadian disruption and ocular surface health, but should be interpreted with caution given the observational design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.